Interpreting Baseline Profiles and PFS Outcomes in High-Risk Smoldering Multiple Myeloma

This segment focuses on the baseline characteristics of patients enrolled in the AQUILA trial and the interpretation of progression-free survival outcomes. Faculty review key demographic and disease-related features, including age, risk stratification, and baseline disease burden, and discuss how representative the study population is of patients seen in routine clinical practice.

The discussion then turns to the primary endpoint, with panelists examining the magnitude and durability of the progression-free survival benefit observed with subcutaneous daratumumab compared with active monitoring. Attention is given to the early and sustained separation of the Kaplan–Meier curves and what this pattern may suggest about disease control over time in a high-risk, yet asymptomatic, population.

Throughout the segment, faculty emphasize the importance of contextualizing these findings within individual patient scenarios, including how progression-free survival improvements may factor into shared decision-making with patients who feel well at the time of treatment consideration.